Global Kinetics Corporation (GKC), a digital health company from Australia that makes tech for people with Parkinson’s disease (PD), announced new sets of data gleaned from reports of PD patients who use their product. They’ve also announced a partnership with the Parkinson’s Foundation for a multi-center, randomized controlled study with over 400 patients to achieve reimbursement for U.S. payers.
Three years ago, we covered GKC’s FDA approval and were excited about the insight their Personal KinetiGraph (PKG) would give to PD patients and their neurologists. Earlier this year, GKC was given European clearance for the watch-like device that tracks the wrist movement and acts as a medication reminder for those with PD. Again, we were pleased with the device and also the added updates.
The scope of this recently-announced study is also impressive and important as Filip Bergquist, associate professor in the department of neurology at Sahlgrenska University Hospital in Sweden, states:
“Even though literature suggests that more than 75 percent of PD patients develop motor fluctuations, no one knows how large the need for dose adjustments or advanced treatments really is.”
The study included 10,000 “de-identified” datasets from PKG users around the world, over a five-year period, and showed a significant variation of PD movement depending on the location. The company surmises this may be due to treatments available. Consistent in all locations, however, was the “sub-optimal” control of PD symptoms among the group studied.
Bergquist goes on to say:
This descriptive study indicates that there is substantial room for improvement, and it should be followed by population-based studies as well as evaluations of whether the availability of objective measurements will improve outcomes.